NO961046L - Fremgangsmåte for behandling av pasienter med akutt hjerteinfarkt som ikke gjennomgår trombolytisk behandling med hirudin og acetylsalicylsyre - Google Patents

Fremgangsmåte for behandling av pasienter med akutt hjerteinfarkt som ikke gjennomgår trombolytisk behandling med hirudin og acetylsalicylsyre

Info

Publication number
NO961046L
NO961046L NO961046A NO961046A NO961046L NO 961046 L NO961046 L NO 961046L NO 961046 A NO961046 A NO 961046A NO 961046 A NO961046 A NO 961046A NO 961046 L NO961046 L NO 961046L
Authority
NO
Norway
Prior art keywords
hirudin
patients
acetylsalicylic acid
undergo
treatment
Prior art date
Application number
NO961046A
Other languages
English (en)
Other versions
NO961046D0 (no
Inventor
Hubert Dr Heinrichs
Charles H Hennekens
Original Assignee
Behringwerke Ag
Brigham & Womens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Behringwerke Ag, Brigham & Womens Hospital filed Critical Behringwerke Ag
Publication of NO961046D0 publication Critical patent/NO961046D0/no
Publication of NO961046L publication Critical patent/NO961046L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A61K38/58—Protease inhibitors from animals; from humans from leeches, e.g. hirudin, eglin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Det er oppdaget at administrering av kombinasjonen av hirudin og acetylsalicylsyre (ASA) til pasienter som ikke gjennomgår behandling med et trombolytisk middel, inhiberer og/eller forhindrer myokardial eller kardiovaskulære tilstander i pasienten. Det er beskrevet en farmasøytisk kombinasjon av et blodplate inaktiverende medikament, acetylsalicylsyre og en direkte trombininhibitor, hirudin, for behandling av pasienter med akutt myokardial infarkt som ikke gjennomgår trombolyse. En farmasøytisk sammensetning som omfatter den synergistiske kombinasjonen av hirudin og ASA, i fravær av et trombolytisk middel, er spesielt nyttig i terapeutiske og profylaktiske i metoder som er beskrevet.
NO961046A 1995-03-15 1996-03-14 Fremgangsmåte for behandling av pasienter med akutt hjerteinfarkt som ikke gjennomgår trombolytisk behandling med hirudin og acetylsalicylsyre NO961046L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40526995A 1995-03-15 1995-03-15
US44055695A 1995-05-12 1995-05-12

Publications (2)

Publication Number Publication Date
NO961046D0 NO961046D0 (no) 1996-03-14
NO961046L true NO961046L (no) 1996-09-16

Family

ID=27019016

Family Applications (1)

Application Number Title Priority Date Filing Date
NO961046A NO961046L (no) 1995-03-15 1996-03-14 Fremgangsmåte for behandling av pasienter med akutt hjerteinfarkt som ikke gjennomgår trombolytisk behandling med hirudin og acetylsalicylsyre

Country Status (14)

Country Link
EP (1) EP0732102A3 (no)
JP (1) JPH0920681A (no)
KR (1) KR960033468A (no)
CN (1) CN1141809A (no)
AR (1) AR002968A1 (no)
AU (1) AU711660B2 (no)
BR (1) BR9601024A (no)
CA (1) CA2171509A1 (no)
FI (1) FI961171A7 (no)
IL (1) IL117485A0 (no)
NO (1) NO961046L (no)
NZ (1) NZ286082A (no)
SG (1) SG43242A1 (no)
UY (1) UY24181A1 (no)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004262776A (ja) * 2003-02-21 2004-09-24 Teikoku Seiyaku Co Ltd 血管新生促進剤
WO2005027896A1 (ja) * 2003-09-19 2005-03-31 Kissei Pharmaceutical Co., Ltd. 併用医薬
US20060222640A1 (en) * 2005-03-29 2006-10-05 Boehringer Ingelheim International Gmbh New pharmaceutical compositions for treatment of thrombosis
CA2657266A1 (en) * 2006-07-17 2008-01-24 Boehringer Ingelheim International Gmbh New indications for direct thrombin inhibitors in the cardiovascular field

Also Published As

Publication number Publication date
AR002968A1 (es) 1998-05-27
FI961171L (fi) 1996-09-16
KR960033468A (ko) 1996-10-22
AU4807296A (en) 1996-09-26
CA2171509A1 (en) 1996-09-16
IL117485A0 (en) 1996-07-23
EP0732102A3 (en) 1999-01-27
FI961171A7 (fi) 1996-09-16
CN1141809A (zh) 1997-02-05
UY24181A1 (es) 1996-03-20
FI961171A0 (fi) 1996-03-13
SG43242A1 (en) 1997-10-17
BR9601024A (pt) 1997-12-30
NZ286082A (en) 1998-09-24
AU711660B2 (en) 1999-10-21
JPH0920681A (ja) 1997-01-21
EP0732102A2 (en) 1996-09-18
NO961046D0 (no) 1996-03-14

Similar Documents

Publication Publication Date Title
FI922325A0 (fi) Oral sammansaettning foer botning av inflammatoriska tarmkanalsjukdomar.
NO20002005D0 (no) Fremgangsmõte for behandling av hyperkoagulable tilstander eller protein C mangel
AR016798A1 (es) Uso de una cepa de lactobacillus para la elaboracion de un medicamento
NO972475L (no) Ny antitrombotisk formulering, fremgangsmåte for dens fremstilling og anvendelse derav
UA41398C2 (uk) Спосіб лікування пацієнта і спосіб зниження ризику кровотеч та крововиливів в мозок у хворого, який потребує тромболітичної терапії, фармацевтична комбінація у формі заздалегідь упакованої одиниці і фармацевтична пакувальна одиниця, що складається з цієї комбінації
WO2004039325A3 (en) Treatment of pain with jnk inhibitors
EP0671414A4 (en) ANTITHROMBOTIC.
LELCUK et al. Inhibition of ischemia-induced thromboxane synthesis in man
AR026254A1 (es) El uso de una preparacion de liberacion controlada para la preparacion de un medicamento para aumentar la dosis o la exposicion sistemica de un farmaco queinhibe la fosfodiesterasa 4
NO943288L (no) Anvendelse av pentoksyfyllin ved fremstilling av farmasöytiske preparater til behandling av granulomatöse og fibroserende lungesykdommer
NO961046L (no) Fremgangsmåte for behandling av pasienter med akutt hjerteinfarkt som ikke gjennomgår trombolytisk behandling med hirudin og acetylsalicylsyre
IL163091A (en) Medical product and pharmaceutical composition comprising as active ingredients a thrombolytic agent and levosimendan or a pharmaceutically acceptable salt thereof and the use of same in the manufacture of medicament for reducing mortality of patients with acute myocardial infarction
MD1521F2 (en) Methods of thrombus forming inhibition, methods of treatment of thrombotic states, pharmaceutical compositions and kit for treatment of thrombotic states
NO934832L (no) Farmasöytisk sammensetning for forhindring eller behandling av arterioscherose
Shulman Heparin and atherosclerosis: an investigative report on the treatment of atherosclerosis
NO953003L (no) Anvendelse av ifenprodil og diastereoisomerer derav for fremstilling av medisinske preparater
US6143742A (en) Treatment for necrotizing infections
DE59908258D1 (de) Blister enthaltend ein transdermales therapeutisches system und eine einzeldosierte darreichungsform
Tejaswi et al. Role of Leech Therapy in the Management of Diabetic Foot Ulcer: A Case Study
Harjola et al. The effect of dipyridamole and warfarin on the patency rate of coronary artery bypass grafts
Brenman Pentoxifylline as adjunctive therapy in leg ulcer management
Boldt RETRACTED: Invited letter concerning: Aprotinin use in pediatric cardiac operations: Reply to the Editor
Marder Thrombolytic agents: Balancing cost, efficacy, and side effects
EA199700025A1 (ru) Применение олигосахарида и аспирина для приготовления медикаментов, предназначенных для лечения тромбоэмболических заболеваний, фармацевтическая композиция, способ лечения
Ellis Jr Tissue expansion as an adjunct to reconstruction of congenital and acquired auricular deformities: Chana JS, Grobbelaar AO, Gault DT. Br J Plast Surg 50: 456, 1997

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application